China Grand Pharmaceutical and Healthcare Holdings Limited

Grand Journey for A Healthier World

2020 GP(HK) ONLINE INVESTOR DAY- Presentation

READ MORE

Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud

READ MORE

First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization of Technological Innovation Pipelines Globally at Full Speed First-mover Advantages in Anti-virus and Anti-infection Area Come into Play

First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization of Technological Innovation Pipelines Globally at Full Speed First-mover Advantages in Anti-virus and Anti-infection Area Come into Play

READ MORE

GP (HK)’s Associate Sirtex Enters into Transactions and Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment and Continues to Propel Global Planning of Technological Innovation

GP (HK)’s Associate Sirtex Enters into Transactions and Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment and Continues to Propel Global Planning of Technological Innovation

READ MORE

GP(HK) and eTheRNA Enters into Exclusive Strategic Cooperation and Licensing Agreement on World-class Innovative Products in Greater China Region Promotes Technology Transfer of mRNA Vaccine Platform to Strengthen International Strategic Planning Covering Multiple Therapeutic Fields with High Innovative Entry Barrier

GP(HK) and eTheRNA Enters into Exclusive Strategic Cooperation and Licensing Agreement on World-class Innovative Products in Greater China Region Promotes Technology Transfer of mRNA Vaccine Platform to Strengthen International Strategic Planning Covering Multiple Therapeutic Fields with High Innovative Entry Barrier

READ MORE

NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA, Actively Promote the Commercialization Process of Innovative Products and Expand Strategic Planning in the Field of Radiopharmaceuticals

NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA, Actively Promote the Commercialization Process of Innovative Products and Expand Strategic Planning in the Field of Radiopharmaceuticals

READ MORE

READ MORE

Popular News

27 Mar

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Results

READ MORE

27 Mar

Yuanda medicine gets sepsis innovative medicine again

READ MORE

27 Mar

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

READ MORE

27 Mar

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

READ MORE

Media Report

Yuanda medicine gets sepsis innovative medicine again

Shanghai Securities News China Securities Network2020-3-27